Abivax SA Sponsored ADR $ABVX Position Lifted by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. boosted its position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 3,436.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 168,705 shares of the company’s stock after purchasing an additional 163,934 shares during the quarter. Jefferies Financial Group Inc. owned 0.19% of Abivax worth $16,705,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Clear Wave Wealth Management LLC grew its holdings in shares of Abivax by 26.2% in the 3rd quarter. Clear Wave Wealth Management LLC now owns 2,979 shares of the company’s stock valued at $295,000 after buying an additional 619 shares during the period. Pictet Asset Management Holding SA raised its stake in Abivax by 4.6% during the 3rd quarter. Pictet Asset Management Holding SA now owns 514,540 shares of the company’s stock worth $50,949,000 after buying an additional 22,472 shares during the period. CenterBook Partners LP raised its stake in Abivax by 321.4% during the 3rd quarter. CenterBook Partners LP now owns 142,496 shares of the company’s stock worth $14,110,000 after buying an additional 108,685 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Abivax during the third quarter worth about $3,200,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Abivax by 15.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,631 shares of the company’s stock worth $1,047,000 after acquiring an additional 1,406 shares in the last quarter. Institutional investors own 47.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Truist Financial decreased their target price on Abivax from $155.00 to $151.00 and set a “buy” rating for the company in a research note on Tuesday, September 22nd. Wedbush dropped their price target on Abivax from $118.00 to $96.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 21st. Piper Sandler reiterated an “overweight” rating on shares of Abivax in a report on Wednesday, October 21st. Barclays reiterated an “overweight” rating and issued a $148.00 price objective on shares of Abivax in a research report on Tuesday, September 22nd. Finally, Guggenheim reissued a “buy” rating and set a $175.00 target price on shares of Abivax in a research note on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $155.00.

Abivax Price Performance

Shares of Abivax stock opened at $91.44 on Thursday. The firm has a market cap of $8.01 billion, a price-to-earnings ratio of -15.09 and a beta of 1.36. The stock’s 50-day moving average is $95.79 and its 200-day moving average is $112.84. Abivax SA Sponsored ADR has a one year low of $69.81 and a one year high of $148.83.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Monday, September 21st. The company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.79). The firm had revenue of $1.37 million during the quarter, compared to the consensus estimate of $0.80 million. On average, equities analysts expect that Abivax SA Sponsored ADR will post -4.14 EPS for the current year.

Abivax Profile

Abivax is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body’s immune response. The company’s lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation. Founded in 2013, Abivax conducts clinical development internationally.